Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정지향 | * |
dc.date.accessioned | 2016-08-27T04:08:26Z | - |
dc.date.available | 2016-08-27T04:08:26Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 1387-2877 | * |
dc.identifier.issn | 1875-8908 | * |
dc.identifier.other | OAK-15909 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217760 | - |
dc.description.abstract | Background: Although plasma amyloid-beta (A beta) levels have been evaluated as a possible diagnostic marker of Alzheimer's disease (AD), the findings are inconsistent. Objective: The present study aimed to validate plasma levels of A beta(40), A beta(42), and the A beta(40)/A beta(42) ratio as biomarkers of AD in subjects with early-onset AD (EOAD) without familial AD genetic mutations. Methods: Patients with sporadic EOAD (sEOAD) were prospectively recruited by nine neurology clinics. Plasma levels of A beta(40) and A beta(42) were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) in 100 sEOAD (50-69 year-old) and 46 age-matched normal control subjects (50-72 year-old). Cerebrospinal fluid (CSF) was obtained from 32 sEOAD subjects and 25 controls. The integrity of the blood-brain barrier was assessed using the CSF/plasma albumin ratio. Results: The plasma levels of A beta(42) were significantly lower, while the A beta(40)/A beta(42) ratio was significantly higher in sEOAD patients than in controls. The levels of A beta(40), A beta(42), and the A beta(40)/A beta(42) ratio did not differ in relation to the APOE epsilon 4 allele. The CSF/plasma albumin ratio was comparable between the two groups, and the plasma parameters of A beta proteins were not significantly associated. A multivariate analysis revealed that an increased A beta(40)/A beta(42) ratio is valuable for the discrimination of sEOAD from controls (beta = 0.344, p = 0.000). The area under the ROC curve for the A beta(40)/A beta(42) ratio was 0.76, and a cut-off ratio of 5.87 was suggested to have 70% sensitivity and 68% specificity. Conclusion: The plasma A beta(40)/A beta(42) ratio had moderate validity for the discrimination of sEOAD patients from age-matched controls. | * |
dc.language | English | * |
dc.publisher | IOS PRESS | * |
dc.subject | Alzheimer's disease | * |
dc.subject | amyloid-beta protein | * |
dc.subject | biomarker | * |
dc.subject | blood-brain barrier | * |
dc.subject | plasma | * |
dc.title | Elevation of the Plasma A beta(40)/A beta(42) Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease | * |
dc.type | Article | * |
dc.relation.issue | 4 | * |
dc.relation.volume | 48 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1043 | * |
dc.relation.lastpage | 1050 | * |
dc.relation.journaltitle | JOURNAL OF ALZHEIMERS DISEASE | * |
dc.identifier.doi | 10.3233/JAD-143018 | * |
dc.identifier.wosid | WOS:000363867300016 | * |
dc.identifier.scopusid | 2-s2.0-84946084657 | * |
dc.author.google | Kim, Hyeong Jun | * |
dc.author.google | Park, Kyung Won | * |
dc.author.google | Kim, Tae Eun | * |
dc.author.google | Im, Ji Young | * |
dc.author.google | Shin, Ho Sik | * |
dc.author.google | Kim, Saeromi | * |
dc.author.google | Lee, Dong Hyun | * |
dc.author.google | Ye, Byoung Seok | * |
dc.author.google | Kim, Jong Hun | * |
dc.author.google | Kim, Eun-Joo | * |
dc.author.google | Park, Kee Hyung | * |
dc.author.google | Han, Hyun Jeong | * |
dc.author.google | Jeong, Jee Hyang | * |
dc.author.google | Choi, Seong Hye | * |
dc.author.google | Park, Sun Ah | * |
dc.contributor.scopusid | 정지향(7402045750;57192068764) | * |
dc.date.modifydate | 20240123101416 | * |